A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)

Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)8 enrolled

Overview

The goal of the study is to learn what happens to different forms of TERN-701 medications in a healthy person's body over time. Researchers will compare what happens to different forms of TERN-701 in a person's body over time. The goal of the study is to learn: * What happens to different forms of TERN-701 in a person's body over time. * The amount and number of different forms of TERN-701 that leave a person's body over time.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

TERN-701DRUG

Oral Liquid radiolabeled with \[14C\]-TERN-701

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has body mass index (BMI) ≥18.5 and ≤32.0 kg/m\^2 * Is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history or presence of any medical condition or prior surgery that may impact typical absorption, distribution, metabolism, or excretion of the orally administered study drug (e.g., gastric bypass, gastrointestinal dysmotility, irritable or inflammatory bowel disease) * Has history or laboratory evidence of hyperthyroidism (thyroid-stimulating hormone \[TSH\] \< lower limit of normal \[LLN\]) or hypothyroidism (TSH ≥8 mIU/L) * Has history of cancer that has not been in complete remission for \> 5 years (except basal cell skin cancer or squamous cell skin cancer with a history of curative treatment and no recurrence for \> 1 year prior) * Has history of dysphagia, aspiration, or other conditions that could potentially impede the ability to safely orally ingest the study drug per protocol * Has history of incomplete bladder emptying with voiding (i.e., urinary retention) or recent history of awakening more than once at night to void * Has usual habit of \< 1 or \> 3 bowel movements per day * Has family history of long QT syndrome or of unexplained sudden death in a first-degree relative under 50 years of age * Has documented congenital or acquired long QT syndrome

Locations (1)

Pharmaron CPC Inc

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine per Sampling Interval (Aeurine,14C,t1-t2)

Urine will be collected to determine the Aeurine,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.